Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

PLAU Antikörper (N-Term)

PLAU Reaktivität: Human, Maus WB, FACS, IHC (p) Wirt: Kaninchen Polyclonal RB04087 unconjugated
Produktnummer ABIN1882148
  • Target Alle PLAU Antikörper anzeigen
    PLAU (Plasminogen Activator, Urokinase (PLAU))
    Bindungsspezifität
    • 8
    • 6
    • 6
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 60-90, N-Term
    Reaktivität
    • 81
    • 24
    • 19
    • 4
    • 3
    • 3
    • 1
    • 1
    Human, Maus
    Wirt
    • 72
    • 13
    • 12
    • 6
    Kaninchen
    Klonalität
    • 78
    • 22
    • 1
    Polyklonal
    Konjugat
    • 58
    • 14
    • 10
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    Dieser PLAU Antikörper ist unkonjugiert
    Applikation
    • 68
    • 56
    • 31
    • 14
    • 12
    • 11
    • 10
    • 9
    • 7
    • 7
    • 6
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Aufreinigung
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This Urokinase (PLAU) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 60-90 amino acids from the N-terminal region of human Urokinase (PLAU).
    Klon
    RB04087
    Isotyp
    Ig Fraction
  • Applikationshinweise
    WB: 1:1000. WB: 1:1000. IHC-P: 1:10~50. FC: 1:10~50
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Haltbarkeit
    6 months
  • Kim, Minai-Tehrani, Kim, Shin, Hong, Kim, Lee, Chang, Yu, Bang, Cho, Yoon, Yu, Jiang, Cho: "Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)-chitosan-graft-spermine." in: Biomaterials, Vol. 33, Issue 6, pp. 1894-902, (2011) (PubMed).

    Eefting, de Vries, Grimbergen, Karper, van Bockel, Quax et al.: "In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase ..." in: Journal of vascular surgery, Vol. 51, Issue 2, pp. 429-37, (2010) (PubMed).

    Bacac, Migliavacca, Stehle, McKee, Delorenzi, Coindre, Guillou, Stamenkovic: "A gene expression signature that distinguishes desmoid tumours from nodular fasciitis." in: The Journal of pathology, Vol. 208, Issue 4, pp. 543-53, (2006) (PubMed).

    Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ..." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 26, pp. 16899-903, (2002) (PubMed).

    Sperl, Jacob, Arroyo de Prada, Stürzebecher, Wilhelm, Bode, Magdolen, Huber, Moroder: "(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, Issue 10, pp. 5113-8, (2000) (PubMed).

    Türkmen, Schmitt, Schmalfeldt, Trommler, Hell, Creutzburg, Graeff, Magdolen: "Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer." in: Electrophoresis, Vol. 18, Issue 5, pp. 686-9, (1997) (PubMed).

    Conne, Berczy, Belin: "Detection of polymorphisms in the human urokinase-type plasminogen activator gene." in: Thrombosis and haemostasis, Vol. 77, Issue 3, pp. 434-5, (1997) (PubMed).

    Yoshimoto, Ushiyama, Sakai, Tamaki, Hara, Takahashi, Sawasaki, Hanada: "Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure." in: Biochimica et biophysica acta, Vol. 1293, Issue 1, pp. 83-9, (1996) (PubMed).

  • Target
    PLAU (Plasminogen Activator, Urokinase (PLAU))
    Abstract
    PLAU Produkte
    Synonyme
    PLAU antikoerper, u-PA antikoerper, ATF antikoerper, BDPLT5 antikoerper, QPD antikoerper, UPA antikoerper, URK antikoerper, uPA antikoerper, UPAM antikoerper, plasminogen activator, urokinase antikoerper, urokinase-type plasminogen activator antikoerper, PLAU antikoerper, CpipJ_CPIJ002131 antikoerper, CpipJ_CPIJ006543 antikoerper, CpipJ_CPIJ013396 antikoerper, CpipJ_CPIJ013623 antikoerper, Plau antikoerper
    Hintergrund
    PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
    Molekulargewicht
    48507
    NCBI Accession
    NP_001138503, NP_002649
    UniProt
    P00749
    Pathways
    Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Autophagie, Smooth Muscle Cell Migration
Sie sind hier:
Kundenservice